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ABSTRACT Glycans decorate proteins and affect their biological function, including
protection against proteolytic degradation. However, pathogenic, and commensal
bacteria have evolved specific glycoproteases that overcome the steric impediment
posed by carbohydrates, cleaving glycoproteins precisely at their glycosylation
site(s). Medically relevant Acinetobacter strains employ their type II secretion system
(T2SS) to secrete the glycoprotease CpaA, which contributes to virulence. Previously,
CpaA was shown to cleave two O-linked glycoproteins, factors V and XII, leading to
reduced blood coagulation. In this work, we show that CpaA cleaves a broader
range of O-linked human glycoproteins, including several glycoproteins involved in
complement activation, such as CD55 and CD46. However, only CD55 was removed
from the cell surface, while CD46 remained unaltered during the Acinetobacter noso-
comialis infection assay. We show that CpaA has a unique consensus target se-
quence that consists of a glycosylated serine or threonine residue after a proline res-
idue (P-S/T), and its activity is not affected by sialic acids. Molecular modeling and
mutagenesis analysis of CpaA suggest that the indole ring of Trp493 and the ring of
the Pro residue in the substrate form a key interaction that contributes to CpaA se-
quence selectivity. Similar bacterial glycoproteases have recently gained attention as
tools for proteomic analysis of human glycoproteins, and CpaA appears to be a ro-
bust and attractive new component of the glycoproteomics toolbox. Combined, our
work provides insight into the function and possible application of CpaA, a member
of a widespread class of broad-spectrum bacterial glycoproteases involved in host-
pathogen interactions.
IMPORTANCE CpaA is a glycoprotease expressed by members of the Acinetobacter
baumannii-calcoaceticus complex, and it is the first bona fide secreted virulence fac-
tor identified in these species. Here, we show that CpaA cleaves multiple targets
precisely at O-glycosylation sites preceded by a Pro residue. This feature, together
with the observation that sialic acid does not impact CpaA activity, makes this en-
zyme an attractive tool for the analysis of O-linked human protein for biotechnical
and diagnostic purposes. Previous work identified proteins involved in blood coagu-
lation as targets of CpaA. Our work broadens the set of targets of CpaA, pointing to-
ward additional roles in bacterium-host interactions. We propose that CpaA belongs
to an expanding class of functionally defined glycoproteases that targets multiple
O-linked host glycoproteins.
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Members of the Acinetobacter baumannii-calcoaceticus complex are a frequentcause of serious multidrug-resistant infections that are associated with high
mortality, and they are a top priority for the research and development of new
antimicrobial therapies (1, 2). However, the development of innovative therapies
against these Gram-negative pathogens demands a better understanding of the viru-
lence and resistance mechanisms critical to Acinetobacter infection. Previous work has
implicated the type II secretion system (T2SS) in the pathogenesis of several Acineto-
bacter spp. in different infection models (3–8). The T2SS is a trans-envelope machine
that mediates the transport of effector proteins from the periplasm to the extracellular
milieu. First, T2SS effectors are translocated to the periplasmic space by either the
general secretory pathway or the twin-arginine translocation (TAT) system (5). Once in
the periplasm, the effectors fold into their tertiary/quaternary structure, a process
occasionally facilitated by dedicated chaperones, and are subsequently targeted to the
T2SS machinery for secretion (7). Although the T2SS machinery is conserved across
Acinetobacter spp., the effector repertoire is diverse and varies from strain to strain (7,
9, 10).
Approximately 20 to 60 T2SS effectors are secreted by any given Acinetobacter
strain, and these proteins are involved in lipid assimilation, serum resistance, coloni-
zation of various host tissues, antibiotic resistance, and biofilm formation (3, 4, 7, 11).
Among these T2SS effectors, the zinc-metallo-endopeptidase CpaA is the best-
characterized and most abundant effector secreted by several medically relevant
Acinetobacter strains (7, 8, 12). We demonstrated that CpaA stability and secretion
depend on the membrane-bound chaperone CpaB, which is encoded adjacent to CpaA
(7, 8). The N-terminal transmembrane domain of CpaB anchors the protein to the
membrane, whereas its C-terminal domain interacts directly with CpaA in the periplasm
(8). Removal of the CpaB transmembrane domain results in secretion of the CpaA-CpaB
complex (8). Structural studies confirmed that CpaA and CpaB strongly interact in a 1:1
ratio via a novel protease-chaperone arrangement in which CpaA surrounds CpaB (8,
13). This unusual configuration was not observed in other previously characterized T2SS
chaperone/effector pairs (14). An additional interesting feature observed in the cocrys-
tal structure is that the CpaB C-terminal tail blocks access to the CpaA catalytic site (13).
In Acinetobacter nosocomialis M2, deletion of cpaA results in virulence defects
comparable to those observed in a T2SS mutant strain (8). Importantly, using a murine
pneumonia model, we demonstrated that CpaA plays a crucial role in dissemination to
the spleen (8). The link between CpaA and dissemination within the host is further
supported by in vitro data showing that CpaA is able to cleave human factor V (fV) and
factor XII (fXII), thus interfering with blood coagulation (12, 15). Interestingly, CpaA
cleaves fXII at two O-glycosylation sites in its proline-rich region, between Pro279Thr280
and Pro308Thr309, with both Thr residues being O glycosylated, though glycans are
known to protect proteins from degradation (15). Moreover, glycosylation is required
for CpaA activity, as deglycosylation of fXII abrogates CpaA activity (15). However, the
full scope of CpaA substrates and the basis for their recognition by CpaA remain poorly
understood.
Few glycoprotein-targeting zinc metallo-endopeptidases have been structurally
characterized. They belong to either the metzincin or gluzincin protease superfamilies
(16, 17). Metzincin proteases have a characteristic extended zinc-binding motif (HEXX-
HXXGXXH) and a conserved Met turn, whereas gluzincin proteases have a glutamate
residue in the zinc-binding motif (HEXXHE) (18). We previously determined the X-ray
crystal structure of CpaA (13). Key features of its catalytic domain (an  fold, an
extended zinc-binding motif, and a conserved Met turn) revealed that CpaA belongs to
the metzincin protease superfamily (13, 19). In addition to its catalytic domain, CpaA
possesses four very similar -sheet tandem repeats, all of which share a similar Ig-like
folds and resemble glycan-binding domains (13, 15). Interestingly, these repeats share
fold similarities to a domain present in the metzincin protease StcE, a secreted
glycoprotease from enterohemorrhagic Escherichia coli (EHEC), though their detailed
sequence and structural similarities are very limited (13, 20). StcE is also a T2SS-secreted
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protease known to target highly O-glycosylated epithelial substrates, such as CD55 (16,
17, 21–23).
Given these reported structural similarities, we hypothesized that CpaA could target
a broader number of glycosylated host proteins. In this work, we combined biochem-
istry, mass spectrometry (MS), molecular modeling and in vivo assays to demonstrate
that CpaA targets multiple O-linked human glycoproteins. This work furthers our
understanding of the interaction of CpaA with its targets and provides valuable insight
into Acinetobacter pathobiology. Furthermore, we show that CpaA has a possible
biotechnological application as a tool for glycoproteomics.
RESULTS
CpaA is a broad-spectrum glycoprotease. Previous reports indicated that CpaA
targets coagulation-related glycoproteins, such as fV and fXII (12, 15). CpaA cleaves the
fXII mucin-like region at two sites (15). Mucins are a family of high-molecular-weight
glycoproteins composed of Pro/Thr/Ser-rich domains that are heavily decorated with
long oligosaccharides (24, 25). While glycosylation is protein dependent, the average
mucin is 50% O-linked glycan by mass, and these glycans tend to be very heteroge-
neous as a result of unique extensions and branching of the core structure (24, 25).
Glycoproteases targeting mucins show a wide variability in terms of substrate prefer-
ences, even among members of the same family, and therefore, prediction of their
targets is not possible (16, 21–23, 26–29). To assess whether CpaA can cleave other
glycoproteins, we expressed and purified CpaA and its catalytically inactive point
mutant (E520A) as C-terminally His-tagged proteins in A. nosocomialis M2, as was
previously done (8, 13). CpaA and CpaAE520A were incubated overnight with several
medically relevant and commercially available glycoproteins (CD55, CD46, TIM1, TIM4,
and C1 esterase inhibitor [C1-INH]), for which their glycosylation is at least partially
characterized. Mucins run as large and diffuse bands as a result of their heterogeneity
in size and glycosylation. Remarkably, CpaA, but not catalytically inactive CpaAE520A,
cleaved all the tested mucin glycoproteins, as observed by gel shifts to lower molecular
weight (Fig. 1A; degradation products are indicated with asterisks). We also tested the
ability of CpaA to cleave two well-characterized recombinant therapeutic glycoproteins,
etanercept (Enbrel) and abatacept (Orencia). These fusion proteins are highly glycosy-
lated proteins purified from mammalian cells and contain mucin-like domains in their
structures (30–32). Once again, CpaA, but not CpaAE520A, cleaved both recombinant
glycoproteins, as observed in Fig. 1B (degradation products are indicated with aster-
isks).
CpaA specifically targets O-linked glycoproteins, and its activity is unaffected
by sialic acid. The activity of glycoproteases is differentially impacted by many factors,
such as O-glycosylation density and glycan composition. For instance, StcE and TagA,
a secreted glycoprotease from Vibrio cholerae, uniquely cleave heavily glycosylated
proteins, such as mucins, but they cannot digest less O-glycosylated proteins, such as
fetuin (Ft). Fetuin, also known as alpha-2-HS-glycoprotein, is decorated with up to five
O-linked sialylated glycans and is often used as a model protein for glycosylation-
related studies (22, 26, 33). In contrast, the activity of other glycoproteases, such as the
gluzincin IMPa from Pseudomonas aeruginosa, is unaffected by the degree of O glyco-
sylation (16). Like IMPa, CpaA cleaved fetuin (Fig. 1C) but not enzymatically deglyco-
sylated fetuin (Fig. 2A). The requirement of glycosylation for CpaA activity is also
supported by the observation that RNase A and bovine serum albumin (BSA) were not
digested by CpaA (Fig. S1A). Furthermore, our results are in agreement with those of
Waack et al., who showed that enzymatically deglycosylated fXII was not cleaved by
CpaA (15).
The activity of various glycoproteases can be dependent on, inhibited by, or
unaffected by the presence of sialic acid, a negatively charged 9-C sugar with key
biological functions (34). For example, glycoproteases from Mannheimia haemolytica
and Clostridium perfringens require sialic acid for activity, whereas other glycoproteases
are inhibited by this sugar (16, 35, 36). StcE is an example of a glycoprotease that is
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indifferent to sialic acid (22). Similarly to StcE, CpaA efficiently digested asialofetuin
(AFt), a variant of fetuin lacking only the sialic acid moieties (Fig. 2B), indicating that
CpaA glycoprotease activity is sialic acid independent.
All of the CpaA targets tested so far were simultaneously N- and O-glycosylated
proteins. To test whether CpaA can cleave N-linked glycoproteins, we incubated CpaA
with RNaseB, a glycoprotein modified only with N-linked glycans. No proteolytic activity
was observed with RNaseB as a substrate (Fig. S1). Together, these results indicate that
CpaA possesses broad substrate specificity, being able to cleave multiple
O-glycosylated proteins in addition to fV and fXII, and that CpaA activity is unaffected
by sialylation.
CpaA cleaves between Pro and a glycosylated Ser/Thr. We employed an MS
approach to gain insight into the common molecular features that dictate CpaA
substrate recognition. We excised the gel pieces containing the proteolysis products
indicated with asterisks in Fig. 1, treated them with trypsin, and subsequently subjected
them to MS analysis, as done previously (37). For most of the proteins, with the
exceptions of TIM4 and C1-INH, we identified nontryptic peptides, resulting from CpaA
activity (Fig. 3 and Fig. S2). These peptides contained an invariant C-terminal Pro
residue (P1 position) (Fig. 3A and Fig. S2A, C, and D), which in the full-length protein
sequences is always adjacent to a glycosylated Ser or Thr (S/T*, where the asterisk
FIG 1 CpaA targets multiple proteins in vitro. Purified mucins (A), mucin-like proteins (B), and fetuin (C)
were treated with purified CpaA and catalytically inactive CpaA (CpaAE520A) (55 kDa). Samples were
separated by SDS-PAGE. Digestion products are indicated by asterisks. These data are representative of
at least 3 independent experiments. C1-INH, C1 esterase inhibitor; TIM, T-cell immunoglobulin and mucin
domain; ENT, etanercept; ABT, abatacept; Ft, bovine fetuin.
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indicates a glycosylated amino acid) (Fig. 3C). We also identified nontryptic glycopep-
tides derived from etanercept that contained a glycosylated N-terminal Ser (Fig. 3B and
Fig. S2B). The peptides were glycosylated with either N-acetyl hexose-hexose-N-acetyl
neuraminic acid (HexNAc-Hex-Neu) or HexNAc-Hex moieties (Fig. 3B and Fig. S2B),
reinforcing the concept that CpaA activity is indifferent to the presence of sialic acid.
The CpaA-dependent cleavage products, including those of fXII (previously reported),
were used as WebLogo inputs (Fig. 3C) (15, 38). This analysis revealed that CpaA has a
distinct peptide consensus sequence, P-S/T*, where cleavage occurred before the
glycosylated Ser/Thr residue. As seen in Fig. 3C, the C-terminal Pro residue preceding
the O-glycosylation site is likely a strict requirement for CpaA targeting. Human
erythropoietin (EPO) contains the same Ser-bound oligosaccharide as fetuin but has an
Ala residue preceding the glycosylation site. This protein was not cleaved by CpaA
(Fig. S1B), further supporting the essentiality of the Pro residue preceding the
O-glycosylation site.
Mammalian glycan array screening. The recombinant proteins tested in this study
were all expressed and purified from HEK293 cells. This cell line generates proteins
O-glycosylated with the disaccharide structure galactose 1-3 N-acetylgalactosamine
(Gal1-3GalNAc), also known as core I, as well as mono- and disialylated core I and core
FIG 2 Fetuin glycosylation is required for CpaA activity. (A) Fetuin and fetuin treated with a deglyco-
sylation mix were incubated with CpaA. Digestion products (indicated with asterisks) are observed only
for fetuin. (B) The presence of sialic acid does not affect CpaA activity. Ft, bovine fetuin; Aft, asialofetuin.
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FIG 3 CpaA cleaves between Pro and a glycosylated Ser/Thr. Mass spectra of the nontryptic fragment of
fetuin (A) and etanercept (B) are shown. The glycosylated Ser residue, indicated in red, is modified with
(Continued on next page)
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II (Gal1-3[GlcNAc1-6]GalNAc) structures (39). Other glycan cores have more complex
(branched) structures that may or may not be accommodated by CpaA (40). To explore
this further, we employed a mammalian glycan array screening assay (performed at the
Consortium for Functional Glycomics) to test if CpaA can directly bind various glycans.
However, we did not detect any significant peak indicative of binding for any glycan in
the array when employing two protein concentrations (5 g/ml and 50 g/ml) of either
CpaA or its catalytically inactive mutant CpaAE520A, (Fig. S3). A similar lack of binding
has been reported for other glycoproteases, which may be due to low-affinity or
transient interactions with the glycans (41). It is noteworthy that none of the glycans in
the glycan array are conjugated to P-S/T sequences. Considering our previous results,
it is likely that recognition by CpaA is dependent on a combination of both protein
sequence and glycan structure adopted in the array.
CD55 is removed from epithelial surfaces by secreted CpaA. Our previous in vitro
results expanded the known CpaA substrates to include human glycoproteins beyond
those involved in blood coagulation (Fig. 1A). To gain insight about CpaA activity in the
context of an infection, we tested whether CpaA directly cleaves surface exposed
O-glycoproteins. Of all the glycoproteins tested in vitro, CD55 and CD46 are highly
expressed cell surface O-glycoproteins in HeLa cells (42). Thus, HeLa cells were treated
with purified CpaA and CpaAE520A, and the levels of CD55 and CD46 bound to the cell
surface were quantified by flow cytometry (Fig. 4). At the two protein concentrations
tested, cells treated with CpaA displayed a reduced amount of CD55 on their surfaces
compared to those treated with CpaAE520A (Fig. 4A). In contrast, although CpaA was
able to cleave CD46 in our in vitro assay (Fig. 1A), levels of cell surface-exposed CD46
remained unaltered after CpaA treatment, independent of the protein concentration
used (Fig. 4B).
Next, we infected HeLa cells with A. nosocomialis M2 expressing CpaA and
CpaAE520A at three different multiplicities of infection (MOI) (10, 100, and 1,000) and
used flow cytometry analysis to quantify the levels of cell surface exposed CD55
FIG 3 Legend (Continued)
HexNAcHexNeuAc. (C) Sequences of the CpaA-dependent cleavage products were used as WebLogo
inputs (weblogo.berkeley.edu). Factor XII cleavage sites were previously reported (15). The underlined
peptide sequences were detected by mass spectrometry. The dashed line indicates the CpaA cleavage site.
HexNAc, N-acetyl hexosamine; Hex, hexose; NeuAc, N-acetyl neuraminic acid.
FIG 4 Purified CpaA cleaves CD55 but not CD46 from HeLa cell surfaces. Surface levels of CD55 (A) and CD46 (B)
were measured by flow cytometry on HeLa cells. Cells were incubated with two different concentrations (2 g/ml
and 5 g/ml) of purified CpaA and CpaAE520A for 1 h. Left and middle panels are representative flow cytometry
histograms. Right panels show the medians and standard deviations (SD) for three biological repeats. ****,
P  0.0001 (two-way ANOVA with Sidak’s multiple-comparison test).
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and CD46 postinfection (Fig. 5). CD55 and CD46 levels remained unchanged when cells
were infected with A. nosocomialis M2 secreting CpaAE520A, indicating that A. nosoco-
mialis M2 does not secrete any other proteases targeting either glycoprotein (Fig. 5). In
agreement with our previous results, secreted CpaA cleaved CD55 but not CD46 from
the cell surface (Fig. 5). The CD46 protein used in the in vitro assay (Fig. 1A) was
expressed and purified from HEK293 cells. It is well known that glycosylation patterns
differ between cell lines (43); thus, it is possible that different protein glycosylation
patterns impact CpaA activity. To address this, we repeated the experiment infecting
HEK293 cells. As observed with HeLa cells, secreted CpaA digested CD55 but not CD46
(Fig. S4), indicating that potential differences in glycosylation between these two cells
lines do not account for these discrepancies. Importantly, an MOI of 100 was sufficient
to detect cleavage of CD55 from HeLa cells, and increasing the MOI to 1,000 did not
boost CD55 cleavage by CpaA (Fig. 5A). The remaining CD55 (and perhaps CD46) may
be associated with proteins/ligands that prevent CpaA activity. We conclude that A.
nosocomialis secretes physiological levels of CpaA that can digest host surface-exposed
proteins during infection.
Molecular modeling identifies a putative mode of binding of glycopeptides to
CpaA. We previously determined the X-ray cocrystal structure of the CpaA-CpaB
complex (13), and others have obtained crystal structures of related metzincin enzymes
with peptide- and peptidomimetic-based ligands (Table 1) (44, 45). X-ray structures of
the related gluzincin glycopeptidases BT4244 (Bacteroides thetaiotaomicron), IMPa, and
ZmpB (Clostridium perfringens ATCC 13124) have also been determined with bound
glyco-amino acid and glycopeptide ligands (16). Notably, these gluzincin enzymes
cleave fetuin, asialofetuin, and related synthetic glycopeptides to various degrees
(Table 1). Thus, to better understand binding between CpaA and glycopeptide sub-
strates, we performed docking experiments between a CpaA model and three different
glycoforms of a fetuin-based fragment peptide (Ac–EAPSA–N-methyl [N-Me], where S is
glycosylated). One of the glycoforms lacks the sialic acid moiety (Fig. 6 and Fig. S5A),
while the other two are sialylated at two different position of the Gal1-3GalNAc core
(Fig. S5B and C). The peptide portions of the docked species were able to contact the
catalytic zinc ion while forming an antiparallel -sheet with a -strand of the active site
(Fig. 6A), findings that are consistent with aforementioned metzincin crystal structures
as well as docking experiments with StcE (16, 22). In the docked structures, the
consensus P1 proline residue lies adjacent to W493 and is somewhat solvent exposed
(Fig. 6B). An H- interaction was observed between a proline beta hydrogen and the
FIG 5 Secreted CpaA cleaves CD55 from HeLa cell surfaces. Surface levels of (A) CD55 and (B) CD46 were measured by flow cytometry
on HeLa cells. Cells were incubated with three different MOI (10, 100, and 1,000) of A. nosocomialis M2 secreting either CpaA or CpaAE520A
for 2.5 h. Representative flow cytometry histograms are shown. Right panels show the medians and SD for three biological repeats. ****,
P  0.0001 (two-way ANOVA with Dunnett’s multiple-comparison test).
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tryptophan indole ring (Fig. 6B). These studies suggest that CpaA selectivity may be the
result of W493 (i) forming a potential H- interaction with the prolyl ring, (ii) minimizing
the prolyl residue’s exposure to solvent, and/or (iii) sterically holding the substrate in
the active site.
In the docked structures, the glycan moieties were found to form few interactions
with CpaA and the substrate peptide. The acetyl group of the GalNAc moieties all
formed hydrogen bonds with the peptide backbone (Fig. 6A). Similar contacts were
observed in docking studies using O-GalNAc-ylated peptides and StcE (22). Such
contacts have been shown to affect the conformation of mucin-like glycopeptides (46),
and they may bias substrates into an extended conformation that would be more easily
recognized by the enzyme. We also found that the 4-OH of the GalNAc moieties formed
hydrogen bonds with the side chain amide of N551 (Fig. 6A and Fig. S5A to C). This
interaction would likely endow the enzyme with selectivity for peptides modified with
GalNAc at P1=. Interestingly, the side chain of this residue occupies space similar to that
of the side chains of tryptophan residues that are conserved in the related gluzincin
enzymes BT4244, IMPa, and ZmpB (Fig. S5D and E). In the gluzincin enzymes, the indole
nitrogens instead hydrogen bond to the acetyl groups of GalNAc ligands. Such a
contact may be formed between CpaA and its substrates if minor conformational
FIG 6 Structure of a fetuin-based model glycopeptide substrate docked in models of CpaA and related
mutants. (A) The enzyme (gray) and the substrate’s peptide portion (green) form hydrogen bonds
(dashed blue lines) between their backbones similar to an antiparallel beta sheet. The catalytic histidine
residues (gray sticks) and zinc ion (gray sphere) hydrolyze the amide bond between the substrate’s
proline (P1) and glycosylated serine (P1=) residues. The GalNAc moiety (yellow sticks) forms hydrogen
bonds with the substrate and the enzyme, whereas the Gal moiety (yellow sticks) is exposed to solvent.
(B to E) The tryptophan residue of the native enzyme can form an H- interaction (dashed orange lines)
with the substrate. This is interaction is weakened when this residue is mutated to phenylalanine and
nonexistent with aliphatic residues.
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changes occur. In either case, N551 appears to be the main residue recognizing the
unique features of the GalNAc moiety, as the other residues flanking the glycans are
mostly small and nonpolar. The related gluzincin enzymes, on the other hand, form
several contacts between polar side chains and their GalNAc groups.
Larger, linear glycans project subsequent sugar residues into solvent; these groups
are not predicted to interact with CpaA. Branched glycans are not well accommodated
by the enzyme, as the disulfide bond adjacent to the active site limits the flexibility of
the enzyme and the branched sugar’s ability to bind. Conversely, both IMPa and ZmpB
form interactions with additional sugars of their corresponding glycans. Still, only IMPa
demonstrated binding activity in the mammalian glycan array screen (16), which may
explain why no hits were found in the same screen with CpaA. Collectively, our docking
studies indicate that CpaA interacts with both peptide and glycan components of the
substrate and identify residue W493 as a potential mediator of the interaction between
CpaA and the Pro residue of its substrate.
Effect of W493 on CpaA specific activity. Docking studies suggest an H- inter-
action between the indole ring (of W493) of CpaA and a beta hydrogen of Pro residue
(at the P1 position) of the substrate (Fig. 6B). While other substrate residues can form
this contact with W493, the unique rigidity and geometry of Pro allow it to optimally
present its beta hydrogen to the indole ring of W493. Thus, we hypothesized that W493
of CpaA plays a critical role in CpaA selectivity. Indeed, our molecular docking studies
indicate a weaker H- interaction when peptides were docked into a mutant W493F
model (Fig. 6C). The modeled W493L and W493A mutants have aliphatic residues that
are unable to form this interaction with the substrate (Fig. 6D and E). Moreover, all the
mutant models formed fewer van der Waals contacts with the Pro residue and further
exposed it to solvent.
To complement our molecular modeling experiments, we tested the effect of these
mutations on CpaA activity. All CpaA point mutation variants were expressed and
secreted at levels similar to those of CpaA and CpaAE520A, and no degradation products
of CpaA were observed in the whole-cell fractions of the CpaA variants (Fig. S6A and B).
CpaAE520A was included as a negative control for CpaA activity. We purified all His-
tagged CpaA variants and determined their in vitro activities against various substrates
(Fig. 7A and Fig. S6C and S7). The different mutations affected CpaA efficiency and site
recognition in a substrate-specific manner. All mutants except CpaAE520A were able to
cleave fetuin, yielding a similar cleavage pattern (Fig. 7A). However, CpaAW493A
cleaved fetuin with less efficiency. None of the CpaA variants were able to cleave EPO,
further highlighting the essentiality of a Pro residue at P1 for targeting by CpaA
(Fig. 7B). Treatment of CD55 and C1-INH with the CpaA mutants revealed that all
variants are less active, as shown by an increase in the amounts of undigested
substrate. Additional faint bands were observed, but we were unable to determine the
cleavage site using MS analysis (Fig. S7).
We previously identified three cleavage sites for CpaA on the mid-region of etan-
ercept, Pro207Thr208, Pro215Ser216, and Pro225Ser226 (Fig. 3B and Fig. S2). Cleavage by
CpaA generates two fragments of similar molecular weights that comigrate as a single
band of about 36 kDa in SDS-PAGE (Fig. 1A and 7C). Notably, digestion of etanercept
by CpaAW493A and W493L generated a major product of 45 kDa instead (Fig. 7C).
CpaAW493F produced three bands that migrate as 36-, 40-, and 45-kDa fragments,
respectively (Fig. 7C). MS analysis of these bands allowed the identification of the sites
preferentially cleaved by the three CpaA variants (Fig. 7D). The unique 45-kDa band
results from cleavage at the Pro183Thr184 site, which is not a preferred site for wild-type
CpaA. Unlike the other cleavage sites, the Pro183Thr184 site is in an area of low
glycosylation of etanercept. Interestingly CpaAW493A and W493L variants were unable
to cleave etanercept in the high-glycosylation-density region, which could explain the
low activity against other mucin targets. Taken together, our data suggest that W493,
although is not essential for activity, plays a role in CpaA substrate selectivity by
interacting with the Pro residue of its target protein.
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CpaA belongs to an expanding, functionally defined class of surface-exposed
and secreted glycoproteases. Mounting evidence indicates that both commensal and
pathogenic species produce and secrete glycoproteases to modulate adherence, pen-
etrate the inner mucus layer, or evade the host immune response (18, 21, 47). For
example, StcE contributes to immune evasion during EHEC infection by preventing
immune cells from moving to the sites of infection (20, 23, 48, 49). Additionally, StcE
activity against mucins promotes access of EHEC to epithelial cells, which assists host
cell colonization (20, 50). P. aeruginosa produces IMPa, which cleaves the macrophage
surface protein CD44, inhibiting phagocytosis (29). IMPa also cleaves P-selectin glyco-
protein ligand 1 (PSGL-1), helping the bacterium to escape neutrophil attack (29). In
Vibrio cholerae, secreted TagA targets host cell surface glycoproteins, modulating
bacterial attachment during infection (26). These examples are indicative of the pivotal
role of glycoproteases in modulating host-pathogen interactions by targeting various
host proteins. Despite their relevance, only a relatively small number of bacterial
glycoproteases have been biochemically characterized to various extents (Table 1).
These enzymes are commonly encoded by bacteria isolated from mucin-rich environ-
ments, such the human gut and lungs. These glycoproteases differ in their secretion
mechanisms, protease class, domain organization, catalytic site, and recognized targets.
Like IMPa, StcE, TagA, and SslE/YghJ, CpaA is secreted by a T2SS. CpaA, IMPa, and ZmpC
display broad O-glycoprotease activity targeting mucins, regardless of their glycosyla-
tion density, as well as O-glycoproteins with low O-glycan chain density (fetuin). On the
other hand, StcE can cleave only mucins with long mucin-like regions (such as CD43
and CD55) or short mucin-like regions (such as C1-INH). In contrast, other glycopro-
teases can target only a subset of mucins. For example, TagA requires more extensive
densely glycosylated regions, whereas SslE/YghJ can digest major mucins such as
MUC2 and MUC3, but it is inactive against mucins like CD43 and bovine submaxillary
mucin (9, 23, 37, 51).
Due to low amino acid sequence conservation, it is not possible to differentiate
proteases from glycoproteases solely on the basis of primary amino acid sequence.
FIG 7 W493 affects CpaA activity. Fetuin (A), EPO (B), and etanercept (C) were incubated with purified CpaA and the different CpaA
mutants (55 kDa). Samples were separated by SDS-PAGE, and gels were stained with InstantBlue. Digestion products are indicated
by asterisks. Undigested products are indicated by arrowheads. These data are representative of at least 3 independent experiments.
(D) Fragment of the etanercept protein sequence. MS analysis of proteins bands allowed the identification of the sites preferentially
cleaved by the four CpaA variants. All the known O-glycosylation sites are in green, and, the Ps next to the glycosites are in bold. The
dashed lines indicate the cleavage sites of CpaA and the different point mutants.
Haurat et al. ®
September/October 2020 Volume 11 Issue 5 e02033-20 mbio.asm.org 12
 on N
ovem











However, structural analyses revealed the presence of Ig-fold domains in all these
enzymes (Table 1, domains in yellow). Moreover, several factors impact substrate
targeting by glycoprotease, including glycan chain identity and density, as well as
amino acid composition (Table 1). Although some target motifs are known, the
molecular bases for the recognition of specific target sequences remain poorly under-
stood. Thus, even if structural analyses identify putative glycan-binding domains in a
protein of interest, it is difficult to predict the specific substrates targeted by the
putative glycoprotease. Together with the functional analysis, these studies define a
functional class of secreted O-glycoproteases that mediate host-pathogen and host-
commensal interactions.
DISCUSSION
Glycan chains decorate proteins to accomplish many different functions. One im-
portant role of glycosylation is the protection of proteins against proteolytic degrada-
tion. However, there is growing evidence that bacterial pathogens and commensals
have evolved specific proteases that overcome the steric impediment posed by car-
bohydrates and indeed use glycans as recognition determinants to cleave glycopro-
teins right at the glycosylation site. In this work, we functionally characterized CpaA, a
metzincin glycoprotease and T2SS-secreted virulence factor of several medically rele-
vant Acinetobacter strains (4, 7, 8, 12). Previous work identified the blood coagulation
proteins fV and fXII as targets of CpaA, suggesting a potential role in dissemination by
interfering with the intrinsic coagulation pathway (4, 8, 12). The present work expands
the known targets of CpaA and indicates that CpaA is a broad-spectrum enzyme with
the ability to cleave various O-linked human glycoproteins. Our MS analysis of proteo-
lytic fragments resulting from glycoprotein treatment with CpaA revealed that CpaA
has a consensus target sequence consisting of a Pro residue followed by a glycosylated
Ser or Thr (P-S/T), which is unprecedented for bacterial glycoproteases. Unlike other
secreted glycoproteases, CpaA activity is not affected by sialic acid and is not restricted
to highly O-glycosylated proteins (mucins). Indeed, CpaA also cleaves sparsely
O-glycosylated proteins, such as fetuin. Although broad-spectrum secreted or surface-
exposed glycoproteases appear to be widespread in bacteria, their identification can-
not be assigned based on sequence homology, and biochemical and structural analyses
are required to designate them as glycoproteases.
CpaA is composed of four very similar Ig-like domains and a catalytic domain (13).
The catalytic domain located at the C terminus of CpaA exhibits all the canonical
structural features of the metzincin superfamily. The four Ig-like domains are arranged
in tandem, and they resemble the insertion domain of StcE, secreted by EHEC (13).
These observations prompted us to further characterize CpaA activity. The StcE-specific
motif S/T*-X-S/T (the asterisk denotes the glycosylation site) diverges from the P-S/T*
motif recognized by CpaA (22). It is intriguing that despite recognizing different motifs,
StcE and CpaA share the substrates C1-INH and CD55. Considering the different domain
organization of the two proteases, it is not surprising that the proteins are classified in
different metzincin subfamilies and target different proteins.
We previously showed that the substrate-binding cleft of CpaA is formed by
residues from its four Ig-like domains and its catalytic domain (13). Thus, to be
recognized by CpaA, the glycosylated substrate has to expose the P-S/T* peptide bond
targeted for hydrolysis. It has been proposed that the interaction of the O-glycans with
residues in the Ig-like domains (referred to as G sites by Noach et al. [16]) help to
position the targeted peptide bond in the correct conformation to interact with the
amino acids involved in catalysis (13, 16). Here, we show that CpaA activity is unaffected
by the presence of sialic acid, indicating that the sialic acid can be accommodated
inside the cleft but is not required for glycopeptide recognition. Our molecular mod-
eling of CpaA with glycosylated substrates showed that linear glycans modified by sialic
acid project this moiety away from the active site and into solvent, which supports our
in vitro findings. Our modeling also revealed a possible interaction between the indole
ring of W493 and the ring of the Pro residue in the targeted sequence. Although the
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digestion of glycoproteins with W493 mutants displayed substrate-specific behaviors,
overall, the mutants were less active and, in some cases, exhibited a shift in glycosyl-
ation site (glycosite) preference. We propose that CpaA selectivity may, at least in part,
be the result of W493 forming a potential H- interaction with the prolyl ring,
minimizing the prolyl residue’s exposure to solvent, and/or sterically holding the
substrate in the active site. Further structural and biochemical studies are required to
uncover the structural features that enable CpaA to target such a remarkably broad
range of O-linked glycoproteins.
CpaA expression and secretion occur across several medically relevant Acinetobacter
strains. Deletion of CpaA resulted in attenuation of A. nosocomialis M2 virulence in a
respiratory murine infection model, playing a role in the dissemination from the lungs
to the spleen (8). Previously, the only known substrates for CpaA were fV and fXII,
proteins involved in blood coagulation. By digesting these proteins, CpaA increases the
clotting time of human plasma (12, 15). We have now shown that CpaA can indeed
cleave multiple proteins in vitro. Among these are several proteins involved in regula-
tion of complement activation, including CD55 and CD46. However, only CD55 was
removed from the cell surfaces, while CD46 remained unaltered during the A. nosoco-
mialis infection assay. We hypothesize that CD46 interacts with another protein that
blocks CpaA access. Thus, not all CpaA targets identified by our in vitro experiments are
representative bona fide targets of CpaA in vivo. An additional role of CD55 is to act as
an anti-adhesive molecule that regulates the release of neutrophils (52). Degrada-
tion of CD55 increases the retention of the neutrophils to the apical epithelial
surface with the concomitant reduction of the amount of neutrophils that cross the
epithelium (48, 49). CpaA expression and secretion are conserved across several
medically relevant Acinetobacter strains isolated from diverse anatomical sites (8).
We aligned the amino acid sequences of CpaA from A. nosocomialis M2 and several
medically relevant A. baumannii strains (Fig. S8). We observed extremely high
protein identity, suggesting that our findings can be extended to CpaA orthologs
secreted by A. baumannii. Considering the broad-spectrum activity of CpaA and the
abundance of glycosylated proteins in the human host, we propose that the
physiological role of CpaA likely extends beyond interfering with the coagulation
pathway or complement cascade. Further work will be required to understand the
full extent of host immunomodulation by CpaA.
Host mucins and O-glycoproteins are major components of mucus, and they are
ubiquitously expressed on cellular surfaces, where they act as physical barriers, receptor
ligands, and mediators of intracellular signaling (53, 54). O-Glycoproteins and mucins
lack a consensus sequence for O-glycosylation, and their O-linked glycans are highly
heterogeneous in their glycan composition, numbers of residues, and linkages. How-
ever, aberrant mucin expression and glycosylation are also linked to various disease
states, making mucins reliable biomarkers (54). For example, the mucin MUC1 is
aberrantly expressed in the majority of cancers diagnosed each year in the United
States. (53). Thus, the assessment of the mucin glycosylation status has high relevance
for diagnosis of cancer and other diseases. Mucin domains are resistant to most
commercially available proteases, which makes them difficult to analyze by traditional
MS strategies. Bacterial glycoproteases have recently gained attention as tools for
proteomic analysis of human glycoproteins (16, 22, 55). Our study shows that the
broad-spectrum O-linked glycoprotease activity of CpaA is not affected by sialic acids.
Moreover, it consistently digests any O-linked glycoprotein containing the P-S/T*
sequence. These properties not only make CpaA a versatile enzyme modulating host-
pathogen interactions but also highlight it as a robust and attractive new component
of the glycoproteomics toolbox.
MATERIALS AND METHODS
Strains, plasmids, and growth conditions. Bacterial strains and plasmids used in this study can be
found in Table S1. E. coli Stellar and A. nosocomialis M2 cells were grown in Lennox broth (LB) at 37°C.
pWH1266-based plasmids were selected with tetracycline (5 g/ml).
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Generation of CpaA point mutations. The PCR primers used for site-directed mutagenesis are listed
in Table S1. To generate CpaAW493 variants, pWH-cpaA-his-cpaB was used as the template. PCR was
carried out using Phusion DNA polymerase (Thermo Scientific). Site-directed mutagenesis was performed
according to the method described by Fisher and Pei (56). Reaction products were transformed into E.
coli Stellar cells and transformants were selected on LB agar supplemented with tetracycline. Mutagen-
esis was confirmed by DNA sequencing. The plasmids were then electroporated into the electrocom-
petent A. nosocomialis M2 ΔcpaAB::frt strain.
Protein purification. CpaA-His and its point mutation variants were purified from the supernatant
of A. nosocomialis M2 (8). Briefly, A. nosocomialis M2 ΔcpaAB::frt strains carrying the pWH-based plasmids
were grown in LB to mid-log phase. CpaA-His-tagged variants were purified by nickel affinity chroma-
tography from cell-free filtered spent medium, as described before (8). Briefly, cells were pelleted at
8,000  g for 10 min. Cell-free supernatants were obtained by filtration using a Nalgene Rapid-Flow filter
unit (pore size, 0.2 m) (Thermo Scientific), followed by concentration by approximately 3-fold using an
Amicon Ultra-15 centrifugal filter unit (nominal molecular weight limit [NMWL], 10,000). Binding buffer
(10) was added to the cell-free supernatant prior to loading onto a nickel-nitrilotriacetic acid (Ni-NTA)
agarose column (Gold Bio, St. Louis, MO) equilibrated with 1 binding buffer (50 mM NaH2PO4, 300 mM
NaCl, 10 mM imidazole; pH 8.0). The column was washed with 20 column volumes (CV) of binding buffer
and 10 CV of sashing buffer (50 mM NaH2PO4, 300 mM NaCl, 50 mM imidazole; pH 8.0). Proteins were
eluted with elution buffer (50 mM NaH2PO4, 300 mM NaCl, 300 mM imidazole; pH 8.0). The purified
proteins were concentrated, and buffer was exchanged for 20 mM HEPES, 150 mM NaCl, 50% glycerol (pH
7.4) using Amicon Ultra centrifugal filter units.
CpaA activity assay. Purified CpaA-His-tagged variants (60 g/ml) were assayed in reaction buffer
(20 mM HEPES [pH 7.4], 150 mM NaCl, 1 mM ZnCl2) containing the substrates proteins (200 g/ml) in a
final volume of 15 l. All reaction mixtures were incubated at 37°C overnight. Reactions were monitored
by SDS-PAGE, with staining with Coomassie blue or InstantBlue. Substrate proteins used in this study
included CD55, CD46, TIM1, TIM4 C1-INH, erythropoietin (Sino Biological), asialofetuin (Sigma), fetuin and
RNase B (New England Biolabs), etanercept (Enbrel), and abatacept (Orencia).
Immunoblotting. Bacterial whole-cell and supernatant samples were prepared as before (7, 8).
Briefly, cultures were grown to an optical density at 600 nm (OD600) of 0.5, and the OD 0.5 cultures were
pelleted by centrifugation and resuspended in 50 l of Laemmli buffer for the whole-cell samples.
Supernatant samples were obtained by trichloroacetic acid (TCA) precipitation of cell-free supernatants
(7, 8). Protein samples were analyzed by SDS-PAGE, transferred to a nitrocellulose membrane, probed
with polyclonal anti-CpaA (1:1,000) (8) and/or monoclonal anti-RNA polymerase (1:2,000; BioLegend).
Western blots were probed with IRDye-conjugated secondary antibodies and visualized with an Odyssey
CLx imagining system (Li-COR Biosciences, Lincoln, NE).
Fetuin deglycosylation. Fetuin was deglycosylated under denaturing conditions using a protein
deglycosylation mix II kit (New England Biolabs) according to the manufacturer’s protocol. Briefly, 100 g
of fetuin was incubated in deglycosylation mix buffer 2 at 75°C for 10 min. After the mixture had cooled,
protein deglycosylation mix II was added, with the exception of one tube to be used as a positive control
for CpaA activity. The glycosylated and deglycosylated fetuin proteins were then used as substrates to
test CpaA activity as described above.
Glycan array. The glycan array binding analysis was performed at the Consortium of Functional
Glycomics (CFG). Two concentrations of purified CpaA (cfg_rRequest_3530) and CpaAE520A (cfg_rRe-
quest_3617) were screened with version 5.4 of the CFG printed array, which consists of 585 glycans in
replicates of 6, according to the standard procedure of the CFG.
Flow cytometry. HeLa cells were maintained in Dulbecco’s minimal essential medium (DMEM) with
high glucose supplemented with 10% (vol/vol) heat-inactivated fetal bovine serum (FBS) (Gibco) at 37°C
and 5% CO2. HEK-293 cells were maintained in Eagle’s minimal essential medium (EMEM) with 10%
(vol/vol) heat-inactivated FBS (Gibco) at 37°C and 5% CO2. Cells were seeded in 60-mm plates at a density
of 1  106 cells per plate a day prior to each experiment. For infection assays, freshly transformed A.
nosocomialis M2 cells with plasmids pWH-cpaA-his-cpaB and pMFH32 were incubated overnight in LB
supplemented with tetracycline. Stationary-phase cultures were normalized to an OD of 1 and washed
three times with phosphate-buffered saline (PBS) before addition to cells at the indicated multiplicity of
infection (MOI) in the respective cell medium. Infected cells were incubated for 2.5 h at 37°C and 5% CO2.
Alternatively, cells were treated with 2 or 5 g/ml of purified CpaA or CpaAE520A, as indicated, and
incubated for 1 h at 37°C and 5% CO2. Following infection or treatment with purified protein, eukaryotic
cells were washed with PBS (twice) and harvested using 0.05% trypsin (Corning). Cells were blocked with
2% (vol/vol) FBS in PBS and labeled with fluorophore-conjugated primary antibodies against CD55
(phycoerythrin [PE]; Sino Biological), and CD46 (allophycocyanin [APC]; Invitrogen). All incubations
were carried out for 45 min on ice, and cells were washed three times with PBS. Labeled cells were
fixed with 4% (vol/vol) paraformaldehyde in PBS for 10 min, washed with PBS, resuspended in PBS
to a cell concentration of 1  106 cell/ml, and filtered prior to analysis. Flow cytometry was
performed on a three-laser, 8-color FACSCanto II cytometer (BD Biosciences). Experiments were
performed in technical triplicates, with 10,000 events analyzed per sample. Data were analyzed using
FlowJo 10.6 (FlowJo LLC), and individual values from three independent experiments (each exper-
iment has at least three technical replicates) were combined and analyzed by two-way analysis of
variance (ANOVA) using GraphPad Prism.
Tryptic digest of gel-separated protein bands. CpaA digested proteins were separated using
SDS-PAGE, fixed, and visualized with Coomassie blue or InstantBlue, as described above. Bands of interest
were excised and processed as previously described (37). Briefly, gel bands were first destained in a
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solution of 50 mM NH4HCO3–50% ethanol for 20 min at room temperature with shaking at 750 rpm.
Destained bands were dehydrated with 100% ethanol, vacuum dried for 20 min, and then rehydrated in
50 mM NH4HCO3 plus 10 mM dithiothreitol (DTT). Protein bands were reduced for 60 min at 56°C with
shaking then washed twice in 100% ethanol for 10 min to remove residual DTT. Reduced ethanol washed
samples were sequentially alkylated with 55 mM iodoacetamide in 50 mM NH4HCO3 in the dark for 45
min at room temperature. Alkylated samples were then washed with 50 mM NH4HCO3 followed by 100%
ethanol twice for 5 min to remove residual iodoacetamide and then vacuum dried. Alkylated samples
were then rehydrated with 12 ng/l trypsin (Promega) in 40 mM NH4HCO3 at 4°C for 1 h. Excess trypsin
was removed, and gel pieces were covered in 40 mM NH4HCO3 and incubated overnight at 37°C.
Peptides were concentrated and desalted using C18 stage tips (57, 58) before analysis by liquid
chromatography (LC)-MS.
Identification of CpaA digestion products and cleavage sites using reverse-phase LC-MS.
Purified peptides prepared were resuspend in buffer A* (0.1% trifluoroacetic acid [TFA], 2% acetonitrile)
and separated using a two-column chromatography setup composed of a PepMap100 C18 20-mm by
75-m trap and a PepMap C18 500-mm by 75-m analytical column (Thermo Fisher Scientific). Samples
were concentrated on the trap column at 5 l/min for 5 min with buffer A (0.1% formic acid, 2% dimethyl
sulfoxide [DMSO]) and infused into an Orbitrap Fusion Lumos Tribrid mass spectrometer (Thermo Fisher
Scientific) at 300 nl/min via the analytical column using a Dionex Ultimate 3000 ultraperformance liquid
chromatograph (UPLC) (Thermo Fisher Scientific). Gradients (45 or 65 min) were run for each sample,
altering the buffer composition from 1% buffer B (0.1% formic acid, 77.9% acetonitrile, 2% DMSO) to 28%
B over 20 or 40 min, then from 28% B to 40% B over 5 min, and then from 40% B to 100% B over 2 min;
the composition was held at 100% B for 3 min, dropped to 3% B over 5 min, and held at 3% B for another
10 min. For 45-min gradients, the Lumos mass spectrometer was operated in a data-dependent mode
automatically switching between the acquisition of a single Orbitrap MS scan (240,000 resolution) every
3 s and MS2 events. For each ion selected, dissociation parameters were as follows. For collision-induced
dissociation (CID), Fourier transform MS (FTMS) was at 15,000 resolution, maximum fill time was 100 ms,
and automatic gain control (AGC) was 2  105. For higher-energy collisional dissociation (HCD), FTMS
was at 15,000 resolution, maximum fill time was 120 ms, normalized collision energy was 35, and AGC
was 2  105. For electron transfer– higher-energy collision dissociation (EThcD), FTMS was at 15,000
resolution, maximum fill time was 120 ms, supplementary activation was 15%, and AGC was 2  105. For
65-min gradients, the Lumos mass spectrometer was operated in a data-dependent mode, automatically
switching between the acquisition of a single Orbitrap MS scan (120,000 resolution) every 3 s and MS2
HCD scans of precursors (normalized collision energy [NCE], 30%; maximal injection time of 22 ms; AGC,
5  104 with a resolution of 15,000). HexNAc oxonium ion (204.087 m/z) product-dependent MS/MS
analysis (59) was used to trigger two additional scans of potential glycopeptides, a CID scan (ion trap MS
[ITMS]; maximum fill time, 100 ms, AGC, 5  104) and an EThcD scan (FTMS, 30,000 resolution; maximum
fill time, 200 ms; supplementary activation, 15%; AGC, 2  105) scan.
Mass spectrometry data analysis. The assessment of the protein coverage within CpaA-digested
bands and the identification of mucin glycopeptides was accomplished using MaxQuant (v1.5.3.30) (60).
Searches were performed against the custom databases populated with the protein sequence of the
recombinant proteins of interest with carbamidomethylation of cysteine set as a fixed modification.
Searches were performed with semitrypsin cleavage specificity allowing 2 miscleavage events. For
the identification of glycopeptide, multiple searches were performed on each sample, allowing
oxidation of methionine and a maximum of three glycan variable modifications using (i) HexNAc
(S/T), HexHexNAc (S/T), HexNAcHexNAc (S/T) or (ii) HexNAc (S/T), Hex(1)HexNAc(1)NeuAc(1) (S/T),
Hex(2)HexNAc(1)NeuAc(1) (S/T). The precursor mass tolerance was set to 20 ppm for the first search and
10 ppm for the main search, with a maximum false discovery rate (FDR) of 1.0% set for protein and
peptide identifications. The resulting protein group output was processed within the Perseus (v1.4.0.6)
(60) analysis environment to remove reverse matches and common protein contaminates. Semitryptic
peptides and semitryptic glycopeptides were manually inspected for correctness. Annotation of MS-MS
provided within the supplementary data was undertaken using the Interactive Peptide Spectral Anno-
tator (60).
Molecular modeling. All computational work was performed using the 2019 Molecular Operating
Environment (MOE 2019.01) software suite (Chemical Computing Group ULC, Montreal, Canada) (61). The
X-ray crystal structures of the metzincin enzymes CpaA (6O38) (13) and serralysin (3VI1), as well as the
gluzincin enzymes IMPa (5KDX, (16), ZmpB (5KDU and 5KDS) (16), and BT4244 (5KD8) (16), were overlaid
using the residues of the highly conserved alpha helix within their active sites (Table S2).
Following a previously described protocol (22), the crystal structure of CpaA was prepared by adding
unresolved side chains and hydrogens as well as capping termini with acetyl or N-methyl (N-Me) groups.
Notably, the crystallographic chaperone protein CpaB was not included during this study. This protein
arranges its C-terminal tail into the CpaA catalytic site, similar to zymogens of related metallopeptidases
(62), and we assume that this portion of CpaB is displaced by substrate.
Peptidomimetic and peptidic ligands have been observed to bind in a similar conformation within
the metzincin active site (44, 45), using the P2-P1= ligand residues to form an antiparallel -sheet with
a -strand of the enzyme active site. Similar to previous work (22), the crystallographic peptide ligand
bound to serralysin (RPKPQQ) was used as a scaffold to construct the peptide portion (Ac–EAPSA–N-Me)
of the fetuin substrate fragment bound to the CpaA model (Table S2). Related gluzincin enzymes were
found to have glycan-containing ligands near the P1= site of their enzyme active sites (16). Thus, the
crystallographic glycan bound to IMPa (Gal1-3GalNAc1) (5KDX) (16) and ZmpB (Gal1-3(Neu5Ac2-
6)GalNAc1) (5KDU) (16) were grafted onto the fetuin peptide fragment to generate corresponding
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glycoforms, and the Glycan Fragment Database (63) was used to identify a glycan (Neu5Ac2-3Gal1-
3GalNAc1) (2CWG) (64) to generate the final glycoform (Table S2).
The glycopeptides were docked into the CpaA model in three steps: conformational search, virtual
screen, and minimization. This process allowed exploration of all reasonable conformations of each
glycopeptide prior to induced-fit docking with the CpaA model. Each glycopeptide underwent a
conformational search using the Amber10:EHT force field (65) to generate a corresponding library of
conformers. During this step, the side chains of the peptide and the pendant groups of each sugar were
allowed to freely rotate; any sialic acid moieties were also allowed to move freely. All other atoms were
fixed. This process generated small libraries of approximately 4,000 conformers for each glycopeptide
species. The conformers of each glycopeptide library underwent virtual screening with the CpaA model,
again using the Amber10:EHT force field. During this process, all atoms of the enzyme and each
glycopeptide were fixed, and the docking score for each resulting complex was calculated using the
GBVI/WSA dG scoring function (66). Finally, the top 10 complexes identified from the virtual screening
were subsequently minimized using the Amber10:EHT force field. The glycopeptide substrate, the
catalytic zinc ion, and residues of the CpaA model having atoms within 10 Å of the substrate were
allowed to move; all other residues were fixed, and solvent molecules were omitted. The best, most
consistent complexes are shown.
This screening and minimization process was repeated for the Gal1-3GalNAc1-modified
glycopeptide conformer library with the mutant CpaA models CpaAW493F, CpaAW493L, and
CpaAW493A. In all cases, the dihedral angles of the peptide backbones (, ) and side chains () as
well as the initial glycosidic linkages (, ) of the docked substrates were measured to ensure proper
geometry.
Data availability. The mass spectrometry proteomics data have been deposited in the ProteomeX-
change Consortium database via the PRIDE (67) partner repository with the data set identifier
PXD019941.
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